Iran Daru (XTEH:IRDR1) Debt-to-EBITDA : 0.00 (As of . 20)

View and export this data going back to 1990. Start your Free Trial

What is Iran Daru Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Iran Daru's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Iran Daru's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Iran Daru's annualized EBITDA for the quarter that ended in . 20 was IRR0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Iran Daru's Debt-to-EBITDA or its related term are showing as below:

XTEH:IRDR1's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.705
* Ranked among companies with meaningful Debt-to-EBITDA only.

Iran Daru Debt-to-EBITDA Historical Data

The historical data trend for Iran Daru's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iran Daru Debt-to-EBITDA Chart

Iran Daru Annual Data

Trend

Debt-to-EBITDA

Iran Daru Semi-Annual Data

Debt-to-EBITDA

Competitive Comparison of Iran Daru's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Iran Daru's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iran Daru's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Iran Daru's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Iran Daru's Debt-to-EBITDA falls into.

Iran Daru Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Iran Daru's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(	+	)	/	N/A
	=	N/A

Iran Daru's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(	+	)	/	0
	=	N/A

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.

Iran Daru (XTEH:IRDR1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Iran Daru Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Iran Daru's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Iran Daru (XTEH:IRDR1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Iran Daru (XTEH:IRDR1) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ayatollah Saeedi Highway, End Of Kermani Street, Moallem Boulevard, Tehran, IRN, 1371658111

Website

https://www.irandaru.com

Iran Daru is a pharmaceutical company based in Iran. It manufactures and sells pharmaceutical products for antibiotics, cardiovascular agents, and local anesthetic agents. The company manufactures products in three main dosage form categories namely solid, semi-solid, and liquid including tablets, capsules, pellets, sachets, gels, creams, ointments (sterile and non-sterile), spray solutions, and syrups. Products offered by Iran Daru include Diclofenac Potassium, Biotin 5 mg, Tetracycline, Folic acid, Meloxicam, Acetaminophen and Caffeine, and Levocetirizine dihydrochloride, among others. It also exports its products to other countries.

Iran Daru (XTEH:IRDR1) Headlines

No Headlines